Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer

2023-508003-20-00 Protocol DS1062-A-U102 Human pharmacology (Phase I) - Other Ended

Start 27 Sep 2021 · End 20 May 2026 · Status Ended · 2 EU/EEA countries · 5 sites · Protocol DS1062-A-U102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 121
Countries 2
Sites 5

Non-small cell lung cancer

Key facts

Sponsor
Daiichi Sankyo Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
27 Sep 2021 → 20 May 2026
Decision date (initial)
2024-06-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-508003-20-00
EudraCT number
2020-006047-25
ClinicalTrials.gov
NCT04526691

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-small cell lung cancer

VersionLevelCodeTermSystem organ class
21.1 PT 10061873 Non-small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Daiichi Sankyo Inc.

Sponsor organisation
Daiichi Sankyo Inc.
Address
211 Mount Airy Road
City
Basking Ridge
Postcode
07920-2311
Country
United States

Scientific contact point

Organisation
Daiichi Sankyo Inc.
Contact name
clinical trial office

Public contact point

Organisation
Daiichi Sankyo Inc.
Contact name
clinical trial office

Locations

2 EU/EEA countries · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 5 1
Spain Ended 32 4
Rest of world
Taiwan, Japan, United States
84

Investigational sites

Italy

1 site · Ended
Fondazione IRCCS San Gerardo Dei Tintori
Oncologia medica, Via Giovanni Battista Pergolesi 33, 20900, Monza

Spain

4 sites · Ended
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Puerta De Hierro De Majadahonda
Medical Oncology, Calle De Manuel De Falla 1, 28222, Majadahonda
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario 12 De Octubre
Medical Oncology, Bloque D, Avenida De Cordoba Sn, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2021-09-29 2026-05-20 2022-03-31 2023-02-14
Spain 2021-09-27 2026-04-28 2021-10-25 2023-06-13

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-17 Italy Acceptable
2024-06-21
2024-06-21
2 SUBSTANTIAL MODIFICATION SM-1 2024-10-29 Italy Acceptable
2024-12-10
2024-12-10
3 SUBSTANTIAL MODIFICATION SM-2 2025-06-13 Italy Acceptable
2025-08-13
2025-08-19
4 SUBSTANTIAL MODIFICATION SM-3 2026-01-12 Italy Acceptable
2026-03-13
2026-03-17